Alnylam

Alnylam seeks FDA approval for lumasiran in primary hyperoxaluria type 1
Pharmaceutical Business Review
Wed, 04/8/20 - 10:51 am
Alnylam
Primary Hyperoxaluria
FDA
lumasiran
After putting aside a bitter legal feud, Alnylam and Dicerna chiefs make nice with an RNAi collaboration
Endpoints
Mon, 04/6/20 - 10:29 am
Alnylam
Dicerna
John Maraganore
Douglas Fambrough
RNAi
Merck
Vir and Alnylam expand collaboration to advance investigational RNAi therapeutics targeting host factors for treatment of COVID-19
Pharmaceutical Business Review
Fri, 04/3/20 - 11:15 am
Vir Biotechnology
Alnylam
COVID-19
RNAi
drug development
Alnylam Pharmaceuticals and Gen sign distribution agreement in Turkey for ONPATTRO (patisiran)
Pharmaceutical Business Review
Thu, 03/26/20 - 10:22 am
Alnylam
RNAi
Gen
Onpattro
Turkey
hATTR amyloidosis
Alnylam, Vir team up to develop siRNAs to tackle COVID-19
Fierce Biotech
Wed, 03/4/20 - 10:52 am
Alnylam
Vir Biotechnology
RNAi
coronaviruses
COVID-19
siRNA
Ex-Sanofi chief Olivier Brandicourt, current Blackstone advisor, jumps on Alnylam board
Endpoints
Fri, 02/28/20 - 10:44 am
Sanofi
Olivier Brandicourt
Alnylam
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
Wed, 01/15/20 - 10:59 am
drug pricing
Roche
Eli Lilly
Amgen
Alnylam
Sanofi
JPM: Alnylam CEO looks to action-packed 2020 on the heels of Givlaari approval
Fierce Pharma
Tue, 01/14/20 - 10:44 am
Alnylam
RNAi
Givlaari
John Maraganore
JPMHC 2020
3 Rare Disease Drug Launches to Watch in 2020
Motley Fool
Sat, 01/4/20 - 07:38 pm
Global Blood Therapeutics
sickle cell disease
Oxbryta
Novartis
SCD
Adakveo
Alnylam
Givlaari
acute hepatic porphyria
FDA
With trial win, Alnylam to seek approval for first treatment of rare kidney disease
Biopharma Dive
Tue, 12/17/19 - 10:29 am
Alnylam
lumasiran
clincial trials
RNAi
kidney disease
Primary Hyperoxaluria
5 New Drug Approvals the FDA Gave Top Priority
Motley Fool
Sat, 11/30/19 - 11:22 pm
FDA
drug approvals
Global Blood Therapeutics
Oxbryta
Alnylam
Givlaari
BeiGene
Brukinsa
Vertex Pharmaceuticals
FDA Approves 5 New Costly Drugs Well Ahead of PDUFA Dates
RAPS.org
Wed, 11/27/19 - 12:39 pm
FDA
Vertex Pharmaceuticals
Trikafta
Novartis
Adakveo
Alnylam
Givlaari
BeiGene
Brukinsa
Global Blood Therapeutics
Oxbryta
drug approvals
Second RNAi Drug Approved: Biotech Investors Should Pay Attention to This New Drug Class
Motley Fool
Sat, 11/23/19 - 04:05 pm
RNAi
Givlaari
Alnylam
FDA's rapid review pace nets an early approval for Alnylam's second drug
Biopharma Dive
Wed, 11/20/19 - 10:51 pm
FDA
Alnylam
Givlaari
givosiran
RNAi
porphyria
The Week Ahead In Biotech: Clinical Readouts In Focus As Earnings Wind Down
Yahoo/Benzinga
Sun, 11/17/19 - 08:47 pm
AHA
The Medicines Company
Intrexon
Alnylam
Pieris
Roche
These Biotechs Were Focused on One Line on Pfizer’s Earnings Report
Motley Fool
Thu, 10/31/19 - 11:51 pm
Pfizer
Vyndaqel
Alnylam
Akcea Therapeutics
Ionis Pharmaceuticals
Eidos Therapeutics
Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
EP Vantage
Sat, 10/19/19 - 01:36 pm
Novartis
fevipiprant
severe asthma
Alnylam
lumasiran
Primary Hyperoxaluria
Pfizer's Vyndaqel franchise, buoyed by diagnoses, is poised for 'a decisive beat': analyst
Fierce Pharma
Fri, 10/18/19 - 07:45 pm
Pfizer
tafamidis
FDA
Vyndaqel
Alnylam
Ionis
ATTR amyloidosis
Alnylam's Onpattro back in the game against Ionis, thanks to NICE U-turn
Fierce Pharma
Tue, 07/9/19 - 06:32 pm
Ionis
Tegsedi
RNAi
Alnylam
Onpattro
NICE
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
Xconomy
Mon, 05/20/19 - 09:41 am
The Medicines Company
Alnylam
inclisiran

Pages